Abstract：Objective: To investigate the effects of 5-aminolevulinic acid (ALA) and/or imatinib mesylate on the content of porphyrin and the expression of ABCG2 protein in HSC-2 of keratinocytes and basal cell carcinoma of HaCaT, and to provide theoretical basis for further improving the clinical efficacy of PDT. Methods: HaCaT keratinocytes and HSC-2 basal cell carcinoma cell lines were cultured with or without imatinib mesylate. The content of ABCG2 protein was determined by Western blotting, the content of porphyrin in cells was detected by ELISA, and the location of porphyrin in cells was observed by confocal laser scanning microscope. Results: In HaCaT cells and HSC-2 cells, the combination of ALA and imatinib mesylate could improve the accumulation of Protoporphyrins in HSC-2 cells, and enhance the cell death induced by PDT. At the same time, compared with the combination of ALA and imatinib mesylate, the combination of ALA and imatinib mesylate could significantly reduce the expression of ABCG2 protein To enhance the killing effect of PDT on HSC-2 cells. Conclusion: This study reveals the possible reasons for the decreased sensitivity of ALA-PDT in the treatment of BCC, and provides a theoretical basis for the further improvement of the efficacy of ALA-PDT combined with imatinib mesylate in the treatment of BCC.
[1] Ibbotson SH, Valentine R, Hearn R. Is the pain of topical photodynamic therapy with methyl aminolevulinate any different from that with 5-aminolaevulinic acid[J].Photodermatol Photoimmunol Photomed, 2012, 28(5):272~273. [2] Ibbotson SH, Ferguson J. Ambulatory photodynamic therapy using low irradiance inorganic light-emitting diodes for the treatment of non-melanoma skin cancer: an open study[J]. Photodermatol Photoimmunol Photomed, 2012, 28(5):235~239. [3] Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria[J]. Proc Natl Acad Sci, 2002, 99(24):15649~15654. [4] Hiraga T, Ito S, Nakamura H. Side population in MDA-MB-231 human breast cancer cells exhibits cancer stem cell-like properties without higher bonemetastatic potential[J]. Oncol Rep, 2011, 25(1):289~296. [5] Ogino T, Kobuchi H, Munetomo K, et al. Serum-dependent export of protoporphyrin IX by ATP-binding cassette transporter G2 in T24 cells[J]. Mol Cell Biochem, 2011, 358(2):297~307. [6] Bebes A, Nagy T, Bata-Csorgo Z, et al. Specific inhibition of the ABCG2 transporter could improve the efficacy of photodynamic therapy[J].Photochem Photobiol B, 2011, 105(2):162~166. [7] Liu W, Baer MR, Bowman MJ, et al. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2[J]. Clin Cancer Res, 2007, 13(8): 2463~2470. [8] Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer[J]. Br Dermatol, 2012, 166(5):1069~1080. [9] Ji Z, Yang G, Vasovic V, et al. Subcellular localization pattern of protoporphyrin IX is an important determinant for its photodynamic efficiency of human carcinoma and normal cell lines[J].Photochem Photobiol B, 2006, 84(3):213~220. [10] Milla LN, Cogno IS, Rodriguez ME, et al. Isolation and characterization of squamous carcinoma cells resistant to photodynamic therapy[J].Cell Biochem, 2011, 112(9):2266~2278. [11] Kriska T, Korytowski W, Girotti AW. Role of mitochondrial cardiolipin peroxidation in apoptotic photokilling of 5-aminolevulinate-treated tumor cells[J]. Arch Biochem Biophys, 2005, 433(2):435~446. [12] Chen X, Zhao P, Chen F, et al. Effect and mechanism of 5-aminolevulinic acid-mediated photodynamic therapy in esophageal cancer[J]. Lasers Med Sci, 2011, 26(1):69~78. [13] Sharma S, Jajoo A, Dube A. 5-Aminolevulinic acid-induced protoporphyrin-IX accumulation and associated phototoxicity in macrophages and oral cancer cell lines[J].Photochem Photobiol B, 2007, 88(2):156~162.
2020, Vol. 26 
冀公网安备13080202000677号